Osteoporosis and Sarcopenia最新文献

英文中文

Addressing challenges in osteoporosis management in Vietnam 应对越南骨质疏松症管理的挑战

IF 2.8 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-09-01 DOI: 10.1016/j.afos.2025.08.043

Tuan V. Nguyen

引用次数: 0

Are there associations between bone turnover and hip geometry in the general population? 在一般人群中，骨转换和髋关节几何形状之间是否存在关联？

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.05.007

Cornelius Sebastian Fischer , Till Ittermann , Sarah Kalmbach , Moritz Herbst , Tina Histing , Jörn Lange , Anke Hannemann

Objectives

While impaired bone remodeling contributes to osteoporosis and probably to osteoarthritis, the relations between bone turnover and key hip geometry measures such as center-edge angle (CE), neck-shaft angle (NSA) or alpha angle remain unknown. We here examined the presence of associations between two bone turnover markers with hip geometric measures in adults from the general population.

Methods

Data from 2037 participants (50% women) in the Study of Health in Pomerania-TREND were examined. Hip geometric parameters were obtained using magnetic resonance imaging. Serum concentrations of carboxy-terminal telopeptide of Type I collagen (CTX, bone resorption) and intact amino-terminal propeptide of Type I procollagen (P1NP, bone formation) were measured to assess bone turnover.

Results

In sex-specific linear regression models adjusted for age, body mass index and physical inactivity, positive associations between CTX or P1NP and CE and inverse associations with NSA were detected. The latter were restricted to men. Thus, an increase in bone formation or resorption is related to less dysplastic (both sexes). Additionally, men with more valgus hips have lower bone turnover markers. For the alpha angle, no significant association was present.

Conclusions

The observed associations between bone turnover markers and hip geometry confirm the presence of relevant relations between bone properties and hip geometry. This knowledge may aid in detection of vulnerable groups with respect to osteoarthritis and fracture risk.

虽然骨重塑受损可导致骨质疏松并可能导致骨关节炎，但骨转换与髋几何指标（如中心边缘角（CE）、颈轴角（NSA）或α角）之间的关系尚不清楚。我们在此研究了普通人群中两种骨转换标记物与髋关节几何测量之间的关联。方法对来自波美拉尼亚健康研究（trend）的2037名参与者（50%为女性）的数据进行分析。通过磁共振成像获得髋关节几何参数。测定血清I型胶原羧基末端末端肽（CTX，骨吸收）和I型前胶原完整氨基末端前肽（P1NP，骨形成）的浓度，以评估骨转换。结果在年龄、体重指数和缺乏运动的性别线性回归模型中，CTX或P1NP与CE呈正相关，与NSA呈负相关。后者仅限于男性。因此，骨形成或骨吸收的增加与较少的发育不良有关（无论男女）。此外，髋外翻较多的男性，其骨转换标志物也较低。对于α角，不存在显著的关联。结论观察到骨转换标志物与髋关节几何形状之间的相关性，证实了骨特性与髋关节几何形状之间存在相关关系。这一知识可能有助于检测易受骨关节炎和骨折风险影响的人群。

{"title":"Are there associations between bone turnover and hip geometry in the general population?","authors":"Cornelius Sebastian Fischer , Till Ittermann , Sarah Kalmbach , Moritz Herbst , Tina Histing , Jörn Lange , Anke Hannemann","doi":"10.1016/j.afos.2025.05.007","DOIUrl":"10.1016/j.afos.2025.05.007","url":null,"abstract":"<div><h3>Objectives</h3><div>While impaired bone remodeling contributes to osteoporosis and probably to osteoarthritis, the relations between bone turnover and key hip geometry measures such as center-edge angle (CE), neck-shaft angle (NSA) or alpha angle remain unknown. We here examined the presence of associations between two bone turnover markers with hip geometric measures in adults from the general population.</div></div><div><h3>Methods</h3><div>Data from 2037 participants (50% women) in the Study of Health in Pomerania-TREND were examined. Hip geometric parameters were obtained using magnetic resonance imaging. Serum concentrations of carboxy-terminal telopeptide of Type I collagen (CTX, bone resorption) and intact amino-terminal propeptide of Type I procollagen (P1NP, bone formation) were measured to assess bone turnover.</div></div><div><h3>Results</h3><div>In sex-specific linear regression models adjusted for age, body mass index and physical inactivity, positive associations between CTX or P1NP and CE and inverse associations with NSA were detected. The latter were restricted to men. Thus, an increase in bone formation or resorption is related to less dysplastic (both sexes). Additionally, men with more valgus hips have lower bone turnover markers. For the alpha angle, no significant association was present.</div></div><div><h3>Conclusions</h3><div>The observed associations between bone turnover markers and hip geometry confirm the presence of relevant relations between bone properties and hip geometry. This knowledge may aid in detection of vulnerable groups with respect to osteoarthritis and fracture risk.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 50-56"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nutrition and exercise for sarcopenia treatment 营养和运动治疗肌肉减少症

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.05.008

Hunkyung Kim , Jiwan Kim , Chahee Lee , Seohee Kim

Sarcopenia, the age-related loss of muscle mass, strength, and performance, is a significant concern in the aging population. Despite extensive research, no consensus exists on its prevention and treatment. Sarcopenia increases the risk of functional disability, falls, hospitalization, long-term care, morbidity, and mortality among older adults.

Currently, no approved pharmacological treatments for sarcopenia exist, making exercise and nutrition the most effective interventions. Evidence indicates that targeted exercise reduces risk factors, preventing or treating sarcopenia in older adults. Progressive, moderate-intensity exercise, alone or combined with nutritional supplementation, is recommended to mitigate muscle deterioration associated with aging. While non-pharmacological interventions are the primary approach, conflicting evidence exists regarding the most effective exercise and nutrition strategies. This review highlights that single intervention, such as exercise or nutritional supplementation alone, provide limited benefits for preventing or treating sarcopenia. In contrast, combined interventions, comprehensive exercise training and nutritional supplementation, effectively improve clinical indicators, including muscle mass, strength, and gait speed, in older adults with sarcopenia.

骨骼肌减少症是一种与年龄相关的肌肉质量、力量和运动能力的丧失，是老龄化人口中一个值得关注的问题。尽管进行了广泛的研究，但对其预防和治疗尚无共识。骨骼肌减少症增加老年人功能残疾、跌倒、住院、长期护理、发病率和死亡率的风险。目前，还没有批准的药物治疗肌肉减少症，运动和营养是最有效的干预措施。有证据表明，有针对性的运动可以减少风险因素，预防或治疗老年人的肌肉减少症。渐进的、中等强度的运动，单独或结合营养补充，被推荐用于减轻与衰老相关的肌肉退化。虽然非药物干预是主要的方法，但关于最有效的运动和营养策略存在相互矛盾的证据。这篇综述强调，单一的干预措施，如单独的运动或营养补充，对预防或治疗肌肉减少症的益处有限。相比之下，综合运动训练和营养补充等联合干预措施可以有效改善老年肌肉减少症患者的临床指标，包括肌肉质量、力量和步态速度。

{"title":"Nutrition and exercise for sarcopenia treatment","authors":"Hunkyung Kim , Jiwan Kim , Chahee Lee , Seohee Kim","doi":"10.1016/j.afos.2025.05.008","DOIUrl":"10.1016/j.afos.2025.05.008","url":null,"abstract":"<div><div>Sarcopenia, the age-related loss of muscle mass, strength, and performance, is a significant concern in the aging population. Despite extensive research, no consensus exists on its prevention and treatment. Sarcopenia increases the risk of functional disability, falls, hospitalization, long-term care, morbidity, and mortality among older adults.</div><div>Currently, no approved pharmacological treatments for sarcopenia exist, making exercise and nutrition the most effective interventions. Evidence indicates that targeted exercise reduces risk factors, preventing or treating sarcopenia in older adults. Progressive, moderate-intensity exercise, alone or combined with nutritional supplementation, is recommended to mitigate muscle deterioration associated with aging. While non-pharmacological interventions are the primary approach, conflicting evidence exists regarding the most effective exercise and nutrition strategies. This review highlights that single intervention, such as exercise or nutritional supplementation alone, provide limited benefits for preventing or treating sarcopenia. In contrast, combined interventions, comprehensive exercise training and nutritional supplementation, effectively improve clinical indicators, including muscle mass, strength, and gait speed, in older adults with sarcopenia.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 54-64"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for osteoporosis 系统可用药全基因组孟德尔随机化确定骨质疏松症的治疗靶点

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.06.001

Chiyun Sun , Ruikang Liu , Jiaming Hu , Weiming Fan , Chuanrui Sun , Pengcheng Shan , Xu Wei

Objectives

The aim of this study was to find potential drug targets of osteoporosis (OP) through systematic druggable genome-wide Mendelian randomization (MR) analysis.

Methods

Combining the multi-omics data, we utilized drug target MR and mediation MR to search for potential drug targets of OP and their possible pathways. Functional enrichment analyses were used to identify metabolic pathways of potential drug targets. In addition, we performed a two-sample MR analysis to investigate the causal relationship between immunoexpression and OP. Finally, we conducted Phe-MR analysis and drug prediction to determine the indications, potential side effects, and pharmacological activities of previously tested targets.

Results

We screened three potential targets of OP-TAS1R3, TMX2, and SREBF1. Mediation MR analysis revealed that body mass index, type 2 diabetes, and chemokine C-C motif ligand 4 may be mediators for the above targets to act on OP. The Steiger Filtering test did not find a reverse causality. The results of functional enrichment analysis showed that the identified target genes may affect OP through lipid metabolism, immune expression, and insulin resistance. Two-sample MR analysis showed that HLA-DR expression in multiple monocyte subpopulations was associated with OP. The five drugs including sucrose, mirtazapine, aspartame, ginsenoside and ezetimibe are identified as the most probable candidates for the treatment of OP. Phe-MR found that TAS1R3 was associated with lower systolic blood pressure, TMX2 with neurologic and lipid metabolism, and SREBF1 with muscle power.

Conclusions

Our study provides evidence support for TAS1R3, TMX2, and SREBF1 as drug targets for OP.

目的通过系统的可用药全基因组孟德尔随机化（MR）分析，寻找治疗骨质疏松症（OP）的潜在药物靶点。方法结合多组学数据，利用药物靶向MR和介导MR寻找OP的潜在药物靶点及其可能通路。功能富集分析用于鉴定潜在药物靶点的代谢途径。此外，我们还进行了双样本MR分析，以探讨免疫表达与op之间的因果关系。最后，我们进行了Phe-MR分析和药物预测，以确定先前测试靶点的适应症、潜在副作用和药理活性。结果我们筛选出了OP-TAS1R3、TMX2和SREBF1三个潜在靶点。中介MR分析显示，体重指数、2型糖尿病和趋化因子C-C基序配体4可能是上述靶点作用于op的中介。Steiger过滤试验未发现反向因果关系。功能富集分析结果表明，鉴定的靶基因可能通过脂质代谢、免疫表达和胰岛素抵抗等途径影响OP。两样本MR分析显示，HLA-DR在多个单核细胞亚群中的表达与op相关，蔗糖、米氮平、阿斯巴甜、人参皂苷和依折替米贝等5种药物被确定为op最有可能的候选药物。ph -MR发现TAS1R3与降低收缩压有关，TMX2与神经和脂质代谢有关，SREBF1与肌肉力量有关。结论sour研究为TAS1R3、TMX2和SREBF1作为OP的药物靶点提供了证据支持。

{"title":"Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for osteoporosis","authors":"Chiyun Sun , Ruikang Liu , Jiaming Hu , Weiming Fan , Chuanrui Sun , Pengcheng Shan , Xu Wei","doi":"10.1016/j.afos.2025.06.001","DOIUrl":"10.1016/j.afos.2025.06.001","url":null,"abstract":"<div><h3>Objectives</h3><div>The aim of this study was to find potential drug targets of osteoporosis (OP) through systematic druggable genome-wide Mendelian randomization (MR) analysis.</div></div><div><h3>Methods</h3><div>Combining the multi-omics data, we utilized drug target MR and mediation MR to search for potential drug targets of OP and their possible pathways. Functional enrichment analyses were used to identify metabolic pathways of potential drug targets. In addition, we performed a two-sample MR analysis to investigate the causal relationship between immunoexpression and OP. Finally, we conducted Phe-MR analysis and drug prediction to determine the indications, potential side effects, and pharmacological activities of previously tested targets.</div></div><div><h3>Results</h3><div>We screened three potential targets of OP-TAS1R3, TMX2, and SREBF1. Mediation MR analysis revealed that body mass index, type 2 diabetes, and chemokine C-C motif ligand 4 may be mediators for the above targets to act on OP. The Steiger Filtering test did not find a reverse causality. The results of functional enrichment analysis showed that the identified target genes may affect OP through lipid metabolism, immune expression, and insulin resistance. Two-sample MR analysis showed that HLA-DR expression in multiple monocyte subpopulations was associated with OP. The five drugs including sucrose, mirtazapine, aspartame, ginsenoside and ezetimibe are identified as the most probable candidates for the treatment of OP. Phe-MR found that TAS1R3 was associated with lower systolic blood pressure, TMX2 with neurologic and lipid metabolism, and SREBF1 with muscle power.</div></div><div><h3>Conclusions</h3><div>Our study provides evidence support for TAS1R3, TMX2, and SREBF1 as drug targets for OP.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 57-64"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FM - Editorial Board FM -编委会

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/S2405-5255(25)00038-X

引用次数: 0

Hypophosphatasia in childhood: Diagnosis to management 儿童低磷症：诊断到治疗

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.05.003

Minji Im, Sung Yoon Cho

Hypophosphatasia (HPP) is a rare inherited metabolic bone disorder caused by loss-of-function mutations in the ALPL gene, leading to deficient activity of tissue-nonspecific alkaline phosphatase (TNSALP). HPP is diagnosed based on a combination of clinical features, laboratory findings, radiographic findings, and DNA analysis identifying a pathogenic variant of ALPL. Based on the clinical heterogeneity of HPP, the diagnosis of HPP is very challenging. However, the introduction of asfotase alfa, a bone-targeted recombinant TNSALP, has improved the prognosis. Early diagnosis of HPP is essential for timely initiation of enzyme replacement therapy (ERT). This review aims to provide an updated current knowledge on the genetic basis, pathophysiology, epidemiology, clinical classification, diagnosis, and management of HPP, with particular emphasis on ERT and emerging diagnostic approaches.

低磷酸症（HPP）是一种罕见的遗传性代谢性骨疾病，由ALPL基因的功能缺失突变引起，导致组织非特异性碱性磷酸酶（TNSALP）活性不足。HPP的诊断是基于临床特征、实验室检查结果、影像学检查结果和确定ALPL致病性变异的DNA分析的结合。由于HPP的临床异质性，HPP的诊断非常具有挑战性。然而，引入asfotase alfa，一种骨靶向重组TNSALP，改善了预后。HPP的早期诊断对于及时开始酶替代治疗（ERT）至关重要。这篇综述旨在提供关于HPP的遗传基础、病理生理学、流行病学、临床分类、诊断和管理的最新知识，特别强调ERT和新兴的诊断方法。

引用次数: 0

Advancing muscle aging and sarcopenia research through spatial transcriptomics 通过空间转录组学推进肌肉老化和肌肉减少症的研究

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.05.002

Byeong-Don Min , Chae Young Hwang , Doyeong Kim , Sang-Yun Kim , Jayasinghage Nirmani Chathurangika Jayasinghe , Minh Nhat Tran , Sang-Min Park , Ki-Sun Kwon

Sarcopenia, defined as a decline of muscle mass and function with aging, poses significant health challenges. This decline is driven by multiple factors including cellular dysfunction, mitochondrial impairments, oxidative stress, and chronic inflammation, all of which collectively disrupt muscle homeostasis and regeneration. Despite the lack of approved treatments for sarcopenia, the search for effective therapies continues as various pharmacological interventions are currently in the early stage of development. Recent advances in transcriptomics have enhanced our understanding of the molecular and cellular mechanisms underlying skeletal muscle aging. In particular, spatial transcriptomics (ST) has revolutionized the field of sarcopenia research by capturing the spatial context of gene expression to uncover site-specific regulation and cellular interactions within tissues. In this review, we explore the current knowledge of sarcopenia, the mechanisms underlying muscle aging, and recent developments in therapeutic strategies. Furthermore, we examine recent studies employing ST that have provided critical insights into the spatial heterogeneity of muscle aging and atrophy, revealing novel cellular and molecular targets for intervention. By connecting muscle pathophysiology with spatial information, ST holds promise for guiding the development of novel sarcopenia therapies, ultimately improving outcomes for aging populations worldwide.

骨骼肌减少症，定义为肌肉质量和功能随着年龄的增长而下降，对健康构成重大挑战。这种下降是由多种因素驱动的，包括细胞功能障碍、线粒体损伤、氧化应激和慢性炎症，所有这些因素共同破坏了肌肉的内稳态和再生。尽管缺乏批准的治疗肌肉减少症的方法，但寻找有效治疗方法的努力仍在继续，因为各种药物干预目前处于发展的早期阶段。转录组学的最新进展增强了我们对骨骼肌衰老的分子和细胞机制的理解。特别是，空间转录组学（ST）通过捕捉基因表达的空间背景来揭示组织内特定位点的调控和细胞相互作用，彻底改变了肌肉减少症的研究领域。在这篇综述中，我们探讨了目前对肌肉减少症的认识，肌肉老化的机制，以及治疗策略的最新进展。此外，我们研究了最近使用ST的研究，这些研究为肌肉衰老和萎缩的空间异质性提供了重要见解，揭示了新的细胞和分子干预靶点。通过将肌肉病理生理学与空间信息联系起来，ST有望指导新型肌肉减少症疗法的发展，最终改善全球老龄化人口的预后。

{"title":"Advancing muscle aging and sarcopenia research through spatial transcriptomics","authors":"Byeong-Don Min , Chae Young Hwang , Doyeong Kim , Sang-Yun Kim , Jayasinghage Nirmani Chathurangika Jayasinghe , Minh Nhat Tran , Sang-Min Park , Ki-Sun Kwon","doi":"10.1016/j.afos.2025.05.002","DOIUrl":"10.1016/j.afos.2025.05.002","url":null,"abstract":"<div><div>Sarcopenia, defined as a decline of muscle mass and function with aging, poses significant health challenges. This decline is driven by multiple factors including cellular dysfunction, mitochondrial impairments, oxidative stress, and chronic inflammation, all of which collectively disrupt muscle homeostasis and regeneration. Despite the lack of approved treatments for sarcopenia, the search for effective therapies continues as various pharmacological interventions are currently in the early stage of development. Recent advances in transcriptomics have enhanced our understanding of the molecular and cellular mechanisms underlying skeletal muscle aging. In particular, spatial transcriptomics (ST) has revolutionized the field of sarcopenia research by capturing the spatial context of gene expression to uncover site-specific regulation and cellular interactions within tissues. In this review, we explore the current knowledge of sarcopenia, the mechanisms underlying muscle aging, and recent developments in therapeutic strategies. Furthermore, we examine recent studies employing ST that have provided critical insights into the spatial heterogeneity of muscle aging and atrophy, revealing novel cellular and molecular targets for intervention. By connecting muscle pathophysiology with spatial information, ST holds promise for guiding the development of novel sarcopenia therapies, ultimately improving outcomes for aging populations worldwide.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 22-31"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and management 亚太地区肌肉减少型肥胖：流行病学、危险因素和管理

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.05.001

Chun-Feng Huang , Chih-Hsing Wu

Sarcopenic obesity (SO), characterized by the concurrent presence of sarcopenia and obesity, is an emerging public health challenge in the Asia–Pacific region. With rapid population aging and increasing obesity rates, the prevalence of SO is increasing, particularly among individuals over 60 years of age. This condition results from a complex interplay of muscle loss, fat accumulation, chronic inflammation, hormonal changes, and metabolic dysregulation, leading to heightened risks of frailty, disability, cardiovascular disease, and mortality.

Region-specific risk factors, including dietary transitions, reduced physical activity, and socioeconomic disparities, further contribute to its increasing prevalence. While pharmacological options are under investigation, lifestyle modifications remain the cornerstone of prevention and management. Regular resistance training, adequate protein intake, and balanced nutrition are essential for preserving muscle mass while promoting fat reduction. Community-based interventions, such as structured exercise programs, public health campaigns, and urban planning that encourage active aging, are crucial for sustainable long-term outcomes.

The current inconsistency in diagnostic criteria has led to numerous challenges, highlighting the urgent need for consensus. In addition, targeted policies focusing on nutritional education, elderly friendly infrastructure, and access to preventive healthcare are essential to alleviating the burden of SO. A comprehensive approach that integrates lifestyle interventions, clinical advancements, and supportive policies is crucial for effectively addressing the growing impact of SO in the Asia–Pacific region and improving health outcomes for the aging population.

肌少性肥胖（SO）以肌少症和肥胖同时存在为特征，是亚太地区一个新兴的公共卫生挑战。随着人口快速老龄化和肥胖率的增加，SO的患病率正在上升，特别是在60岁以上的人群中。这种情况是由肌肉损失、脂肪积累、慢性炎症、激素变化和代谢失调等复杂的相互作用造成的，导致虚弱、残疾、心血管疾病和死亡的风险增加。特定区域的风险因素，包括饮食转变、身体活动减少和社会经济差异，进一步导致其患病率上升。虽然正在研究药物选择，但改变生活方式仍然是预防和管理的基石。有规律的抗阻训练、充足的蛋白质摄入和均衡的营养是在促进减脂的同时保持肌肉质量的必要条件。以社区为基础的干预措施，如有组织的锻炼计划、公共卫生运动和鼓励积极老龄化的城市规划，对于可持续的长期结果至关重要。目前诊断标准的不一致导致了许多挑战，突出了迫切需要达成共识。此外，注重营养教育、老年人友好型基础设施和获得预防性保健的有针对性的政策对于减轻老年人口负担至关重要。综合生活方式干预、临床进步和支持性政策的综合方法对于有效应对亚太地区SO日益增长的影响和改善老龄化人口的健康结果至关重要。

{"title":"Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and management","authors":"Chun-Feng Huang , Chih-Hsing Wu","doi":"10.1016/j.afos.2025.05.001","DOIUrl":"10.1016/j.afos.2025.05.001","url":null,"abstract":"<div><div>Sarcopenic obesity (SO), characterized by the concurrent presence of sarcopenia and obesity, is an emerging public health challenge in the Asia–Pacific region. With rapid population aging and increasing obesity rates, the prevalence of SO is increasing, particularly among individuals over 60 years of age. This condition results from a complex interplay of muscle loss, fat accumulation, chronic inflammation, hormonal changes, and metabolic dysregulation, leading to heightened risks of frailty, disability, cardiovascular disease, and mortality.</div><div>Region-specific risk factors, including dietary transitions, reduced physical activity, and socioeconomic disparities, further contribute to its increasing prevalence. While pharmacological options are under investigation, lifestyle modifications remain the cornerstone of prevention and management. Regular resistance training, adequate protein intake, and balanced nutrition are essential for preserving muscle mass while promoting fat reduction. Community-based interventions, such as structured exercise programs, public health campaigns, and urban planning that encourage active aging, are crucial for sustainable long-term outcomes.</div><div>The current inconsistency in diagnostic criteria has led to numerous challenges, highlighting the urgent need for consensus. In addition, targeted policies focusing on nutritional education, elderly friendly infrastructure, and access to preventive healthcare are essential to alleviating the burden of SO. A comprehensive approach that integrates lifestyle interventions, clinical advancements, and supportive policies is crucial for effectively addressing the growing impact of SO in the Asia–Pacific region and improving health outcomes for the aging population.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 40-49"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone-muscle interactions 骨筋交互

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.04.001

Hiroshi Kaji

Bone and skeletal muscle jointly govern motor function, working in coordination as anatomically adjacent organs, and collaborate with through mechanical interactions. Bone and muscle cells are both derived from common mesenchymal stem cells. Muscle tissues reportedly support fracture healing and bone repair. Common factors affect muscle and bone simultaneously, and sarcopenia and osteoporosis are complications of various diseases. Research on bone-muscle interactions has progressed in the past 15 years, and clinical evidence has confirmed that a relationship exists between sarcopenia and osteoporosis. Numerous myokines or osteokines play a role in bone-muscle interactions, and the involvement of extracellular vesicles has also been suggested. Research on bone-muscle interactions may translate into clinical applications for the treatment of sarcopenia and osteoporosis.

骨骼和骨骼肌共同控制运动功能，作为解剖学上相邻的器官协调工作，并通过机械相互作用进行协作。骨细胞和肌肉细胞都来源于普通的间充质干细胞。据报道，肌肉组织支持骨折愈合和骨修复。常见因素同时影响肌肉和骨骼，肌肉减少症和骨质疏松症是多种疾病的并发症。骨骼肌相互作用的研究在过去15年中取得了进展，临床证据证实肌肉减少症与骨质疏松症之间存在关系。许多肌因子或骨因子在骨肌相互作用中起作用，细胞外囊泡也被认为参与其中。骨骼肌相互作用的研究可能转化为治疗肌肉减少症和骨质疏松症的临床应用。

引用次数: 0

Molecular crosstalk in SP7-mediated osteogenesis: Regulatory mechanisms and therapeutic potential 分子串扰在sp7介导的成骨：调控机制和治疗潜力

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia

Pub Date : 2025-06-01 DOI: 10.1016/j.afos.2025.04.003

Jun Lang , Vivek Kumar Morya , Mi-Kyung Kwak , Sin-Hye Park , Kyu-Cheol Noh

SP7, also known as Osterix, is a zinc finger-containing transcription factor, plays a crucial role in osteoblast differentiation and bone formation. This review examines the molecular mechanisms underlying SP7's regulatory functions, highlighting its interactions with key signaling pathways such as BMP-SMAD, Wnt/β-catenin, and HIF-1α. SP7 acts downstream of RUNX2 to regulate osteogenic gene expression, including collagen Type I Alpha 1 (COL1A1), alkaline phosphatase (ALP) and osteocalcin (OCN). The review also explores the role of post-translational modifications, such as phosphorylation and ubiquitination, in modulating SP7's stability and activity. Emerging therapeutic strategies targeting SP7, including gene editing, RNA-based approaches, and small-molecule modulators, are discussed as innovative solutions for treating osteoporosis and other skeletal disorders. The potential for future research into SP7's interactions with non-coding RNAs and angiogenesis pathways is emphasized, underscoring its significance in skeletal health and regenerative medicine. This comprehensive overview consolidates current knowledge of SP7's molecular functions, therapeutic potential, and its pivotal role in bone biology.

SP7，也被称为Osterix，是一种含锌指的转录因子，在成骨细胞分化和骨形成中起着至关重要的作用。本文综述了SP7调控功能的分子机制，重点介绍了SP7与BMP-SMAD、Wnt/β-catenin和HIF-1α等关键信号通路的相互作用。SP7作用于RUNX2的下游，调控成骨基因的表达，包括I型胶原α 1 （COL1A1）、碱性磷酸酶（ALP）和骨钙素（OCN）。本文还探讨了翻译后修饰，如磷酸化和泛素化，在调节SP7的稳定性和活性中的作用。针对SP7的新兴治疗策略，包括基因编辑、基于rna的方法和小分子调节剂，作为治疗骨质疏松症和其他骨骼疾病的创新解决方案进行了讨论。未来研究SP7与非编码rna和血管生成途径的相互作用的潜力被强调，强调其在骨骼健康和再生医学中的重要性。这篇全面的综述巩固了SP7的分子功能、治疗潜力及其在骨生物学中的关键作用的现有知识。

{"title":"Molecular crosstalk in SP7-mediated osteogenesis: Regulatory mechanisms and therapeutic potential","authors":"Jun Lang , Vivek Kumar Morya , Mi-Kyung Kwak , Sin-Hye Park , Kyu-Cheol Noh","doi":"10.1016/j.afos.2025.04.003","DOIUrl":"10.1016/j.afos.2025.04.003","url":null,"abstract":"<div><div>SP7, also known as Osterix, is a zinc finger-containing transcription factor, plays a crucial role in osteoblast differentiation and bone formation. This review examines the molecular mechanisms underlying SP7's regulatory functions, highlighting its interactions with key signaling pathways such as BMP-SMAD, Wnt/β-catenin, and HIF-1α. SP7 acts downstream of RUNX2 to regulate osteogenic gene expression, including collagen Type I Alpha 1 (COL1A1), alkaline phosphatase (ALP) and osteocalcin (OCN). The review also explores the role of post-translational modifications, such as phosphorylation and ubiquitination, in modulating SP7's stability and activity. Emerging therapeutic strategies targeting SP7, including gene editing, RNA-based approaches, and small-molecule modulators, are discussed as innovative solutions for treating osteoporosis and other skeletal disorders. The potential for future research into SP7's interactions with non-coding RNAs and angiogenesis pathways is emphasized, underscoring its significance in skeletal health and regenerative medicine. This comprehensive overview consolidates current knowledge of SP7's molecular functions, therapeutic potential, and its pivotal role in bone biology.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"11 2","pages":"Pages 31-37"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Osteoporosis and Sarcopenia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀